TY - JOUR T1 - Antifungal drug resistance: an update JF - European Journal of Hospital Pharmacy JO - Eur J Hosp Pharm SP - 109 LP - 112 DO - 10.1136/ejhpharm-2020-002604 VL - 29 IS - 2 AU - David W Denning Y1 - 2022/03/01 UR - http://ejhp.bmj.com/content/29/2/109.abstract N2 - The number of antifungal classes is small, and resistance is becoming a much more frequent problem. Much greater emphasis needs to be placed on susceptibility testing and antifungal stewardship. Such efforts demonstrably improve survival and overall clinical outcomes. Positively diagnosing a fungal infection with laboratory markers often allows antibacterial therapy to be stopped (ie, anti-tuberculous therapy in chronic pulmonary aspergillosis or antibiotics other than cotrimoxazole in Pneumocystis pneumonia), contributing to antimicrobial resistance control generally. Non-culture based diagnostics for fungal disease are transformational in terms of sensitivity and speed, but only occasionally identify antifungal resistance.No data are available. No specific new data. ER -